Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Where are we in 2023?

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

Alexey Danilov, MD, PhD, discusses treatment developments for patients with mantle cell lymphoma who have progressed on BTK inhibitors.

Callie Coombs, MD, discusses treatment updates in patients with chronic lymphocytic leukemia.